R&D Trends

Shasun, Debiopharm Group ink licensing agreement for Huperzine-A

Wednesday, April 17, 2013 10:46 AM

Shasun Pharmaceuticals, a global pharmaceutical contracting organization, and Debiopharm Group, a Swiss-based global biopharmaceutical group focused on unmet medical needs, entered into a licensing agreement for the manufacturing and commercialization of Huperzine-A.

More... »

Santaris Pharma, BMS form discovery alliance for RNA-targeted medicines

Wednesday, April 17, 2013 09:44 AM

Santaris Pharma, a privately held biopharmaceutical company focused on disease-related mRNAs and microRNAs, has formed a worldwide strategic alliance with Bristol-Myers Squibb to discover and develop novel medicines using Santaris Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform.

More... »

Sony, Olympus launch medical device joint venture

Tuesday, April 16, 2013 02:49 PM

Sony and Olympus have launched Sony Olympus Medical Solutions, a medical business venture that aims to align Sony's cutting-edge electronics technologies in areas such as digital imaging with Olympus' manufacturing and R&D expertise in the area of medical products including lenses and optical technologies in order to bring high-quality medical care to as many people as possible, and contribute to medical advancement worldwide.

More... »

Catalent Biologics expands into ADCs through license with Redwood Bioscience

Tuesday, April 16, 2013 10:34 AM

Catalent Pharma Solutions has acquired an exclusive license to market Redwood Bioscience's proprietary SMARTag precision protein-chemical engineering technology for the development of advanced antibody-drug conjugates (ADCs).

More... »

Inovio, U.S. Army receive $3.5M biodefense grant for mass vaccination device

Friday, April 12, 2013 11:22 AM

Inovio Pharmaceuticals has been selected to receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.

More... »

Cleave Biosciences raises $10M in Series A Financing extension

Wednesday, April 10, 2013 11:13 AM

Cleave Biosciences has raised $10 million in an extension of its Series A financing from new investor New Enterprise Associates (NEA), bringing its Series A total to $54 million. In conjunction with the financing, NEA partner Robert Garland, M.D., has joined Cleave's board of directors.

More... »

Accera, University of Miami to study Axona for cognitive impairment in MS

Wednesday, April 10, 2013 10:44 AM

Accera, a privately-held, commercial-stage healthcare company focused on clinical applications to address acute and chronic neurodegenerative diseases, has formed a collaboration with the University of Miami Miller School of Medicine to study the effects of Accera's medical food, Axona, on cognitive impairment in patients with multiple sclerosis (MS).

More... »

Japan establishes global fund for R&D of new medicines, vaccines, diagnostics

Wednesday, April 10, 2013 10:15 AM

Japan’s first public-private partnership to advance the development of new health technologies for the developing world The Global Health Innovative Technology Fund (GHIT Fund) has officially launched. The GHIT Fund has been established to advance the R&D of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world.

More... »

GSK, A*STAR's ICES to develop new medicines for emerging markets

Wednesday, April 10, 2013 09:17 AM

GlaxoSmithKline and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.\

More... »

Roche, Isis Pharmaceuticals form alliance for Huntington's disease

Monday, April 8, 2013 02:29 PM

Basel, Switzerland-based Roche and Isis Pharmaceuticals of Carlsbad, Calif., have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology.

More... »